[EN] ADENOSINE RECEPTOR BINDING COMPOUNDS<br/>[FR] COMPOSÉS SE LIANT AU RÉCEPTEUR DE L'ADÉNOSINE
申请人:NIKANG THERAPEUTICS INC
公开号:WO2020014332A1
公开(公告)日:2020-01-16
The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.
An expedient approach to the difluoromethylation of imidazoles and benzimidazoles has been developed. The key feature of the procedure is the gradual generation of the difluoromethylation reagent in the reaction mixture, which is achieved by the simultaneous addition of chlorodifluoromethane and alkali. The method is applicable to functionalized substrates and allows the corresponding 1-(difluoromethyl)imidazoles and -benzimidazoles to be prepared in 60-95% yield on a hundred-gram scale.